Skip to main content

Volume 11 Supplement 1

Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review

Review

Edited by Josef Smolen

Publication of this supplement has been sponsored by F. Hoffmann-La Roche.

  1. Conventional disease-modifying antirheumatic drugs such as methotrexate are the mainstay of treatment for rheumatoid arthritis. More recently, biologic agents such as etanercept, infliximab and adalimumab, whi...

    Authors: Andrea Rubbert-Roth and Axel Finckh
    Citation: Arthritis Research & Therapy 2009 11(Suppl 1):S1
    Content type: Review Published on:
  • Logo
Submit manuscript

Follow

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 4.4
    5-year Journal Impact Factor: 4.9
    Source Normalized Impact per Paper (SNIP): 1.294
    SCImago Journal Rank (SJR): 1.518

    Speed 2024
    Submission to first editorial decision (median days): 11
    Submission to acceptance (median days): 118

    Usage 2024
    Downloads: 3,978,337
    Altmetric mentions: 1,452

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us